Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
Nature Communications|August 8, 2024
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Scientific Reports|January 25, 2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancerFrancesco Sclafani, Ian Chau, David Cunningham, et al.
European Journal of Endocrinology|November 30, 2023
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survivalAnna La Salvia, Alberto Lens-Pardo, Angel López-López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Journal of the National Cancer Institute|July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
European Journal of Endocrinology|July 9, 2017
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)Jaume Capdevila, José Manuel Trigo, Javier Aller, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Nature Communications|August 8, 2024
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Scientific Reports|January 25, 2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancerFrancesco Sclafani, Ian Chau, David Cunningham, et al.
European Journal of Endocrinology|November 30, 2023
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survivalAnna La Salvia, Alberto Lens-Pardo, Angel López-López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Journal of the National Cancer Institute|July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
European Journal of Endocrinology|July 9, 2017
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)Jaume Capdevila, José Manuel Trigo, Javier Aller, et al.
Pageof 20